Global Preimplantation Genetic Diagnosis (PGD) Market 2019-2023| Increasing Demand for Early Diagnosis of Genetic Disord

1. Global preimplantation genetic diagnosis market size is forecast to grow by USD 131.99 million during 2019-2023 at a CAGR over 10% with fertility clinics and maternity centers having the largest market share. Preimplantation genetic diagnosis market analysis indicates growth will be driven by increasing demand for early diagnosis of genetic disorders. Growing demand for non- invasive biopsy procedures in PGD will also fuel preimplantation genetic diagnosis industry growth. The market is driven by the increasing demand for early diagnosis of genetic disorders. In addition, the rising adoption of IVF treatments is further anticipated to boost the preimplantation genetic diagnosis (PGD) during the forecast period. Looking for more information on this market? Request a free sample report The need to prevent physical disabilities and health conditions in newborns has increased the demand for early diagnosis during genetic IVF techniques and other artificial insemination procedures. Preimplantation diagnostic tests facilitate the determination of genetic disorders by diagnosing genetic variations at the embryonic stage. Moreover, the availability of support from governments and non-profit organizations to promote the wellbeing of women and children while enabling the early diagnosis of diseases has increased awareness about the early diagnosis of genetic disorders. Thus, such initiatives by governments and non-profit organizations have increased awareness about the early diagnosis of genetic diseases and disorders, which has driven the growth of the global PGD market. Furthermore, healthcare service providers are extensively using advanced reproductive technologies, such as PGD and prenatal diagnosis, which have become an integral part of detecting the presence of genetic diseases and disorders during IVF treatments. Thus, the rising adoption of IVF treatments has increased the demand for PGD. Also, the availability of favorable reimbursements for IVF treatments has helped in addressing concerns about the high cost of these procedures. Therefore, the demand for IVF-based fertility treatments is rising, which is driving the growth of the global PGD market. The report includes detailed profiles of the leading companies & prominent vendors of the market: Genea Ltd. Igenomix Sl Illumina Inc. Invitae Corp. Laboratory Corp. of America Holdings Natera Inc. Oxford Gene Technology Group PerkinElmer Inc. Quest Diagnostics Inc. Thermo Fisher Scientific Inc. Market Segmentation by Category and Product Types: • • • • • • • • • • The Preimplantation Genetic Diagnosis (PGD) Market can be broadly categorized into the following end-user segments:

2. Fertility clinics and maternity centers Hospitals and diagnostic laboratories Research institutes Key Regions for the Preimplantation Genetic Diagnosis (PGD) Market: • • • Featuring a breakdown of region wise market shares until 2019. North America Europe Asia ROW Some of the key topics covered in the report include: • • • • Market Landscape Market ecosystem Market characteristics Market segmentation analysis Market Sizing • • • Market definition Market size and forecast Vendor Landscape • • Vendors covered Vendor classification Market positioning of vendors Competitive scenario • • • • Browse Full Report - http://bit.ly/2Vatg9n